Author(s): Zeng, Yujun ; Xiang, Yufan ; Sheng, Ruilong ; Tomás, Helena ; Rodrigues, João ; Gu, Zhongwei ; Zhang, Hu ; Gong, Qiyong ; Luo, Kui
Date: 2021
Persistent ID: http://hdl.handle.net/10400.13/4080
Origin: DigitUMa - Repositório da Universidade da Madeira
Subject(s): Polysaccharides; Drug delivery systems; Nanomedicines; Cancer immunotherapy; Anticancer efficacy; .; Faculdade de Ciências Exatas e da Engenharia; Centro de Química da Madeira
Cancer immunotherapy is an effective antitumor approach through activating immune systems to eradicate tumors by immunotherapeutics. However, direct administration of “naked” immunotherapeutic agents (such as nucleic acids, cytokines, adjuvants or antigens without delivery vehicles) often results in: (1) an unsatisfactory efficacy due to suboptimal pharmacokinetics; (2) strong toxic and side effects due to low targeting (or off-target) efficiency. To overcome these shortcomings, a series of polysaccharide-based nanoparticles have been developed to carry immunotherapeutics to enhance antitumor immune responses with reduced toxicity and side effects. Polysaccharides are a family of natural polymers that hold unique physicochemical and biological properties, as they could interact with immune system to stimulate an enhanced immune response. Their structures offer versatility in synthesizing multifunctional nanocomposites, which could be chemically modified to achieve high stability and bioavailability for delivering therapeutics into tumor tissues. This review aims to highlight recent advances in polysaccharide-based nanomedicines for cancer immunotherapy and propose new perspectives on the use of polysaccharide-based immunotherapeutics.
